Literature DB >> 12771636

Successful treatment of Candida krusei infection with caspofungin acetate: a new antifungal agent.

William T McGee1, Gary J Tereso.   

Abstract

OBJECTIVE: Systemic fungal infections have high mortality, and therapy is often toxic. Caspofungin acetate, a new antifungal agent with minimal toxicity, may provide a better alternative to typical therapy for Candida krusei.
DESIGN: Case report.
SETTING: Multidisciplinary intensive care unit (ICU) of a community teaching hospital. PATIENT: A 22-yr-old male with acute lymphoblastic leukemia and Candida krusei fungemia failed therapy with fluconazole and amphotericin B.
INTERVENTIONS: Caspofungin acetate given intravenously as a 70-mg loading dose, followed up by 50 mg daily along with standard ICU care.
RESULTS: Survival without toxicity from therapy.
CONCLUSION: Efficacy of caspofungin acetate in a patient with life-threatening Candida Krusei infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771636     DOI: 10.1097/01.CCM.0000063145.15336.31

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  7 in total

1.  On a fatal case of Candida krusei pleural empyema in a pregnant woman with spontaneous esophagus perforation.

Authors:  Antonio Cascio; Mario Barone; Vincenzo Micali; Chiara Iaria; Demetrio Delfino; Antonio David; Maurizio Monaco; Francesco Monaco
Journal:  Mycopathologia       Date:  2010-02-09       Impact factor: 2.574

2.  A case of Candida krusei peritonitis secondary to duodenal perforation due to Candida duodenitis.

Authors:  Antonio Cascio; Marcello Bartolotta; Antonella Venneri; Cinzia Musolino; Chiara Iaria; Demetrio Delfino; Giuseppe Navarra
Journal:  Mycopathologia       Date:  2010-07-15       Impact factor: 2.574

Review 3.  [Therapy of severe fungal infections].

Authors:  M Battegay; U Flückiger
Journal:  Internist (Berl)       Date:  2003-12       Impact factor: 0.743

Review 4.  Invasive candidiasis in pediatric intensive care units.

Authors:  Sunit Singhi; Akash Deep
Journal:  Indian J Pediatr       Date:  2009-11-12       Impact factor: 1.967

5.  Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; E Nagy; S Dobiasova; M Rinaldi; R Barton; A Veselov
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

6.  Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys.

Authors:  Punam Sandhu; Xin Xu; Peter J Bondiskey; Suresh K Balani; Michael L Morris; Yui S Tang; Alisha R Miller; Paul G Pearson
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

7.  Can a biologic mesh survive a Candida krusei infection? A case report of infection of a biologic mesh following repair of abdominal wall hernia.

Authors:  Elfatih I Abter; Keith Apelgren; Gary Salem; Ruben Toribio
Journal:  IDCases       Date:  2014-06-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.